CAR-T Toxicities Consortium
The Chimeric Antigen Receptor (CAR) T-Cell Toxicities Consortium unites investigators from scientific and medical associations, government agencies, and registries, to address emerging toxicities associated with the application of CAR T-cell therapies.
Goals and Objectives
The consortium, consisting of representatives from scientific and medical associations, U.S. Food and Drug Administration (FDA) and the Center for International Blood and Marrow Transplant Research (CIBMTR) working together, will address urgent needs related to emerging CAR-T adverse events and identify opportunities to address the following areas:
- Increasing investigators’ understanding of the molecular mechanisms surrounding these toxicities and the role conditioning regimens could play in their onset.
- Exploring ways to effectively report and catalog these toxicities to inform future research.
- Developing educational resources for clinicians to inform toxicity management approaches.
- Informing regulatory agencies on the challenges and recent developments in the field surrounding this topic.
Current Focus
The consortium is expected to convene on a bi-monthly basis (i.e., every other month) with its first order of business being to conduct a landscape analysis of the field. Based on its assessment, it will then ascertain and develop resources to address important gaps.
Consortium Members
Members consist of individuals who have expertise in CAR-T cells and the ability to carry forward recommendations from this consortium to their respective organizations.
American Society of Hematology
Nirali N. Shah, MD, MHSc, (Chair)
Robert S Negrin, MD, PhD, (Vice Chair)
Alice Kuaban, MS, (Staff Liason)
American Association for Cancer Research
Helen E. Heslop, MD, DSc (Hon)
Nikhil C. Munshi, MD
American College of Rheumatology
Maximilian F. Konig, MD, DSc (Hon)
C. Thomas Appleton, MD, PhD, FRCPC
American Society of Gene and Cell Therapies
Isabelle Riviere, PhD
Marco Davila, MD, PhD
ASH Research Collaborative
Saad Usmani, MD, MBA, FACP, FASCO
William Wood, MD, MPH
American Society for Transplantation and Cellular Therapies
Frederick Locke, MD
Marcela Maus, MD, PhD
Center for International Blood and Marrow Transplant Research
Marcelo Pasquini, MD, MS
Society for Immunotherapy of
Cancer
Kristen Hege, MD
Sarah Warren, PhD
Food and Drug Administration
Nicole Verdun, MD
International Society for Cell and Gene Therapy
Bruce Levine, PhD
Jaap Jan Boelens, MD, PhD
Questions?
For more information on the CAR-T Toxicities Consortium, please contact ASH’s Director of Scientific Affairs, Alice Kuaban, MS at [email protected].
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission